TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1901199
Drug: Separate drugs
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate drugs (isoniazid, rifampin, and pyrazinamide administered separately)
Study: 19946241
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no statin therapy)
Study: 23805813
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus oral hygiene instruction
Study: 20473066
Drug: Desvenlafaxine 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50, 100, 200, or 400 mg/d
Study: 11885569
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan (TRP) depletion (100 g of an amino acid mixture without TRP)
Study: 2501032
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (3.3 cm2)
Study: 2501032
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (6.7 cm2)
Study: 2501032
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (13.3 cm2)
Study: 28832429
Drug: Both HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HT formulations (o-CEE and t-E2)
Study: 27555179
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (DEX) 1 μg/kg
Study: 30562785
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (DEX) 2 μg/kg
Study: 24286456
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of GW766994 twice daily for 10 days followed by prednisone 30 mg for 5 days
Study: 15992231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly meetings only)
Study: 11514924
Drug: Other therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapy
Study: 9422018
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (400 mg) twice daily for two days at 24 weeks of gestation
Study: 8181027
Drug: Nitrate therapy
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate therapy without hydralazine
Study: 8181027
Drug: Nitrates in
Normalized name: organic nitrates in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates in patients treated with ACE inhibitors
Study: 27602705
Drug: Text Messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text Messaging (TM) intervention with 2-way reminders about medication administration.
Study: 26397085
Drug: Supervised spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised spinal stabilization exercises (weekly physical therapy for 8 weeks)
Study: 26397085
Drug: 1-time treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-time treatment followed by home exercises (unsupervised group)
Study: 24653520
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (15 mg/kg)
Study: 23503913
Drug: Intravenous dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dipyrone (15 mg/kg)
Study: 23503913
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol and dipyrone
Study: 18834691
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral hygiene instruction for 20 min.
Study: 9632123
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acarbose with 100 g sucrose
Study: 9632123
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 100 g sucrose
Study: 3205904
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (OT) infusion
Study: 26306883
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) in addition to traditional physical therapy, administered three times per week for three months.
Study: 26306883
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) in addition to traditional physical therapy, administered three times per week for three months.
Study: 18444531
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Epidural Analgesia (Bupivacaine 0.08% + 3 microg/ml of Fentanyl, 6 ml/h and bolus of 5 ml)
Study: 16165104
Drug: LI160 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI160 (2 x 750 mg)
Study: 8772586
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose of GH (0.04 U/kg)
Study: 8772586
Drug: Supraphysiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological dose of GH (0.08 U/kg)
Study: 6503959
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postoperative radiotherapy (total dose 5000 rads, with 3000 rads preoperative) and adjuvant chemotherapy (FT-207, 600mg/day for over 3 months) in group A.
Study: 30282392
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline solution (placebo)
Study: 24813670
Drug: Classroom-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-based cognitive behaviour therapy (CBT)
Study: 21047406
Drug: Oral beta-blockers
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blockers at admission
Study: 21047406
Drug: Oral beta-blockers
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blockers before hospital discharge
Study: 12133040
Drug: eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 40 mg
Study: 12133040
Drug: eletriptan 20
Normalized name: eletriptan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 20 mg
Study: 10088733
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5% ophthalmic solution (Acular) administered four times daily for 14 days
Study: 16792136
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral alfacalcidol (2 microg after each dialysis session)
Study: 16792136
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral alfacalcidol (1 microg given 6 days/week)
Study: 27414159
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg)
Study: 3046537
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline
Study: 1729064
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and salbutamol
Study: 30655255
Drug: Custom administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Custom administration of a standard dose of gadobutrol
Study: 17572643
Drug: Scheduled acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled acetaminophen (665 mg modified-release tablets, three times a day for five days)
Study: 17572643
Drug: As needed
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As needed acetaminophen (665 mg tablets as needed)
Study: 17572643
Drug: As needed
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As needed acetaminophen
Study: 8722438
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg twice a day orally for 12 months)
Study: 6414571
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (ASA/DPM)
Study: 22237003
Drug: Valganciclovir prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir prophylaxis for 200 days (900 mg once daily)
Study: 19931952
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (2007 southern hemisphere influenza vaccine); coverage among ACF residents ranged from 59% to 100%.
Study: 17462091
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care Plus Musculoskeletal Physiotherapy Treatment (UCMT)
Study: 9733427
Drug: Distraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction treatment (20 sessions)
Study: 9733427
Drug: Focusing treatment
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focusing treatment (20 sessions)
Study: 8555030
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine hydrochloride 50 mg once daily for 4 weeks
Study: 6781321
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem 90 mg
Study: 6781321
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin 0.3 mg
Study: 28029390
Drug: Olumacostat glasaretil
Normalized name: Olumacostat glasaretil
DrugBank: Olumacostat glasaretil (DB12642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olumacostat glasaretil (OG) 7.5% gel
Study: 25017924
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral hormone therapy
Study: 25017924
Drug: Non-oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-oral hormone therapy
Study: 17578315
Drug: Ampeptide elemente,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampeptide elemente, 0.4 g three times a day for two weeks, then adjusted to 0.2 g each time for a total of 1.8 g a day for two more weeks.
Study: 15272511
Drug: 25% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazole gel (test)
Study: 18069178
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (control)
Study: 11603386
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-therapy with photopheresis
Study: 8081786
Drug: Intravenous OKT3
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous OKT3 for seven days
Study: 25564143
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg once daily for 4 days
Study: 21485673
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol
Study: 26467455
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment
Study: 17488771
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 60 mg acute loading dose prior to PCI
Study: 15487709
Drug: Cross‐linked hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross‐linked hylan G‐F 20
Study: 9631345
Drug: Expectancy ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy ratings during therapy
Study: 14998068
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg
Study: 28501812
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted physiotherapy assessment and treatment
Study: 24142616
Drug: methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone aceponate 0.1% based cream
Study: 21598242
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel followed by carboplatin (sDC)
Study: 21945310
Drug: Combination docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination docetaxel and carboplatin (cDC)
Study: 19099676
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg/d
Study: 19099676
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast 5 mg, once at bedtime for 6 months
Study: 3631471
Drug: nalbuphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 5 mg
Study: 1416128
Drug: naloxone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 0.2 mg
Study: 27903341
Drug: Propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol group (P group) - received sufentanil 0.1 μg/kg and propofol 1.5 mg/kg followed by a continuous infusion of 3-6 mg·kg-1·h-1 of propofol
Study: 12716662
Drug: Unsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsaturated fatty acids (O, T, L)
Study: 10981217
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities for acute dislocation of the patella; specific treatments not detailed
Study: 10981217
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities for recurrent dislocation of the patella; specific treatments not detailed
Study: 1435590
Drug: Praziquantel therapy
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel therapy at a daily dose of 25 mg/kg for 2 days
Study: 6376718
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination chemotherapy program with CCNU
Study: 6376718
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination chemotherapy program with mechlorethamine
Study: 30202873
Drug: Split-virion inactivated
Normalized name: influenza, inactivated, split virus or surface antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-virion inactivated influenza vaccine
Study: 17894651
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (intermediate exposure category)
Study: 17894651
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (high exposure category)
Study: 23025273
Drug: Horse meat
Normalized name: Horse meat specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse meat consumption (2 portions of 175 g/week)
Study: 16802483
Drug: 1.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml/kg Hartmann's solution
Study: 16802483
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg Hartmann's solution
Study: 10371111
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg daily for 4 weeks)
Study: 3519058
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (20 g)
Study: 28116761
Drug: Daily 1-hour
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1-hour nap opportunity
Study: 21520194
Drug: Maintenance peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance peginterferon treatment
Study: 12592052
Drug: Unoprostone isopropyl
Normalized name: Unoprostone Isopropyl
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unoprostone isopropyl 0.15% ophthalmic solution
Study: 10971309
Drug: Dofetilide 1000
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide 1000 microg, twice daily
Study: 8982131
Drug: poly‐L‐lactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly‐L‐lactic acid screws
Study: 1443810
Drug: Intubated patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubated patients (0.5 and 0.75 ml)
Study: 24844333
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT)
Study: 25223209
Drug: Bromfenac 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 0.1% monotherapy (n = 23)
Study: 11385810
Drug: Novolizer (MDPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 90 l/min
Study: 11385810
Drug: Novolizer (MDPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 60 l/min
Study: 11385810
Drug: Novolizer (MDPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 45 l/min
Study: 11385810
Drug: Pulmicort Turbuhaler
Normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Turbuhaler at peak inhaled flow rate of 60 l/min
Study: 2451954
Drug: 1040 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1040 regimen (cisplatin 80 mg/m2, vincristine 1 mg, methotrexate 10 mg/m2 on days 1, 2, 3, and bleomycin 10 mg/m2 on days 1, 2, 3)
Study: 29536284
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing + Cognitive Behavioral Therapy (MI + CBT)
Study: 26440643
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g polydextrose/d (control)
Study: 23980734
Drug: Resveratrol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol and quercetin combination (RQ)
Study: 18199920
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus hydrochlorothiazide 25 mg
Study: 18199920
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus hydrochlorothiazide 25 mg
Study: 8815701
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with two nucleosides
Study: 1475040
Drug: 1750 mg
Normalized name: vancomycin 1750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1750 mg of the DA antagonist alpha‐methyl‐p‐tyrosine (AMPT)
Study: 1475040
Drug: 0.65 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g/kg ethanol
Study: 27400469
Drug: Decoction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction of Nicotiana tabacum leaves mouthwash (10 mL 3 times a day for 5 days)
Study: 27400469
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash (10 mL 3 times a day for 5 days)
Study: 17645577
Drug: L-T3 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T3 (50 microg qd) for 3 weeks
Study: 8618852
Drug: Viral RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral RNA level < or = 100,000 copies/ml
Study: 25187119
Drug: Zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 5 mg (N=703)
Study: 22045833
Drug: Continuous celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous celecoxib 200 mg/day
Study: 22045833
Drug: Intermittent celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent celecoxib 200 mg/day
Study: 2884081
Drug: Azelastine 4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 4.4 mg
Study: 28059603
Drug: Mastery Learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastery Learning (ML) BLS course
Study: 25782427
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 supplementation (1000 μm phylloquinone, one pearl softgel capsule daily for 4 weeks)
Study: 25782427
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one placebo capsule daily for 4 weeks)
Study: 17660909
Drug: Early-loaded ITI
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-loaded ITI implants (loaded 6 weeks after surgery)
Study: 17660909
Drug: Conventionally-loaded ITI
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventionally-loaded ITI implants (loaded 12 weeks after surgery)
Study: 12227482
Drug: Oral finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral finasteride (1 mg per day)
Study: 12227482
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% minoxidil solution
Study: 2644531
Drug: sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sequential methotrexate and fluorouracil followed by leucovorin
Study: 29858517
Drug: Perineural injections
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural injections